Market News
Stay updated with the latest market trends, earnings, and economic indicators.
BofA sees domestic growth, Semaglutide opportunity driving pharma in FY27
Neha Manpuria, Senior Analyst - Pharma, Healthcare at BofA Global Research, says semaglutide launches could emerge as a key growth driver for Indian pharma companies in FY27.
Stock markets decline for 2nd day on selling in oil, gas, banking shares
Stock markets closed lower for the second consecutive day on Wednesday as investors remained cautious amid conflicting geopolitical signals from the West Asia and fresh foreign fund outflows. In a volatile trade, the 30-share BSE Sensex declined 141.90 points, or 0.19 per cent, to settle at 75,867.80, with 20 of its constituents ending higher and 10 with losses. During the day, it hit a high of 76,224.68 and a low of 75,748.21, gyrating 476.47 points. The 50-share NSE Nifty skidded 6.55 points, or 0.03 per cent, to end at 23,907.15. Sensex had dropped by 479.26 points and Nifty by 118 points on Tuesday. Financials, oil & gas, IT and private banking shares were the major drag while energy, metals, and auto shares advanced, capping the downside. Among 30 Sensex firms, HDFC Bank fell the most by 2.63 per cent. Infosys, ITC, Hindustan Unilever, Reliance Industries and ICICI Bank were also among the major laggards. Power Grid, Eternal, NTPC and Tata Steel were the major ...
Monetise idle household gold, ease compliance burden to build Viksit Bharat: Kotak MF's Nilesh Shah
Nilesh Shah of Kotak Mutual Fund suggests India must unlock its vast household gold reserves. He also calls for easing business regulations. These steps are crucial for India's development. He highlighted significant gold imports and the potential of gold financing. Entrepreneurs are driving innovation despite challenges. Support for businesses is vital for global competition.
RBI should start rate hike cycle as inflation risks rise, says Bandhan MF’s Suyash Choudhary
Average inflation forecasts are likely to move higher, and the RBI should begin the rate hike cycle to maintain its credibility as an inflation-focused central bank, according to Suyash Choudhary, CIO-Fixed Income at Bandhan Mutual Fund. However, he believes rate hikes alone may not immediately solve the problem. He said the RBI must avoid mixed messaging to prevent market uncertainty and added that a favourable mix of global factors — including lower oil prices, better foreign inflows, and a weaker dollar — could help improve the situation.
Diamonds in the dust? Retail investors unleash Rs 17,500 crore on 8 battered bluechip stocks
Retail investors pumped an estimated Rs 17,539 crore into eight battered Nifty bluechip stocks during the March 2026 quarter, betting aggressively on market leaders despite steep declines in portfolio values. HDFC Bank, ITC, Wipro, Infosys, TCS, Reliance Industries and L&T emerged as top retail picks even as their shares fell sharply.
Entero Healthcare Gets Target Price Hike On Strong Q4 Earnings As Jefferies Eyes 17% Upside
Jefferies said Entero's medtech segment is expected to cross Rs 10 billion in FY27 as the business has better margins
Nomura Asset, Capital Group, others buy 5.3% stake in Premier Energies for Rs 2,291 cr
Global financial institutions and Indian mutual funds have bought a 5.3 percent stake in Premier Energies. The deal involved promoters selling shares worth over Rs 2,291 crore. This investment comes as Premier Energies secured significant orders for solar cells and modules. The company is expanding its manufacturing capacities for cells and modules.
Blue Jet Healthcare gains 8% post Q4; analysts split on near-term prospects
Emkay Global has retained its 'Reduce' rating, while Motilal Oswal has maintained its 'Buy' stance, reflecting contrasting expectations on recovery in key business segments and the margin trajectory
Healthcare, engineering and specialty chemicals remain key market themes: Mayuresh Joshi
Mayuresh Joshi, Director Research at Marketsmith India, believes execution will remain key for companies like Suzlon, while healthcare, engineering and select speciality chemical names continue to offer strong growth opportunities. He also sees India-focused engineering and capital goods companies remaining resilient despite global uncertainties. Joshi says investors should stay selective in IT, remains positive on Navin Fluorine, and is closely tracking niche AI-linked opportunities emerging in smaller tech firms.
Sakar Healthcare partners with Zydus Lifesciences for GCC Markets
Sakar Healthcare has partnered with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. This marks the company's 40th global agreement in the anti-cancer segment. Sakar Healthcare is expanding its international oncology business and strengthening its presence in emerging markets. The company is also progressing with regulatory filings and approvals in highly regulated markets.
Engineers India Ltd leads losers in 'A' group
Ganesha Ecosphere Ltd, Central Bank of India, Max Healthcare Institute Ltd and GMR Power & Urban Infra Ltd are among the other losers in the BSE's 'A' group today, 22 May 2026.
Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sector
Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future growth for the Indian healthcare sector. Key drivers include AI-led innovation, incremental advancements in niche areas, and improved quality culture. Attractive valuations also support this positive outlook for the industry.